Erdafitinib (Everest)

💊 Product Overview

Erdafitinib (Brand name: Balversa) is an oral pan-FGFR tyrosine kinase inhibitor used for the treatment of patients with locally advanced or metastatic urothelial carcinoma carrying FGFR2 or FGFR3 genetic alterations.

By blocking fibroblast growth factor receptor (FGFR) activity, Erdafitinib helps interrupt the signaling pathways that cancer cells rely on for growth and spread, providing a precision-targeted anti-cancer treatment approach.

In 2019, Erdafitinib received accelerated approval from the U.S. FDA, becoming the first approved targeted therapy for FGFR-mutated bladder cancer and offering a new treatment option for patients who failed conventional therapies.

✅ Eligible Patients

Erdafitinib may be suitable for patients who:

• Have confirmed FGFR2 or FGFR3 genetic alterations through molecular testing
• Are diagnosed with locally advanced or metastatic urothelial carcinoma
• Have previously received at least one platinum-based chemotherapy regimen
• Are generally able to tolerate oral targeted therapy
• Have been evaluated individually by an oncology specialist

🔬 Note: FGFR mutation testing is required to determine eligibility for Erdafitinib treatment.

🎯 Clinical Efficacy and Data

In the BLC2001 clinical trial, Erdafitinib demonstrated promising activity in patients with FGFR alterations:

• Overall Response Rate (ORR): 40%
• Median Progression-Free Survival (PFS): 5.5 months
• Particularly strong responses were observed in patients with FGFR3 mutations

These results established Erdafitinib as an important targeted therapy option for urothelial carcinoma, especially for patients resistant to or unable to tolerate conventional chemotherapy.

⚠️ Common Side Effects

Possible side effects during treatment may include:

• Hyperphosphatemia (very common and may correlate with treatment activity)
• Mouth sores, dry eyes, and nail changes
• Fatigue, diarrhea, and dry skin
• Blurred vision or other visual disturbances (regular eye examinations are recommended)

Patients are advised to monitor phosphate levels regularly, undergo routine ophthalmologic examinations, and promptly report any unusual symptoms to their healthcare provider.

💡 Dosage and Administration

The recommended starting dose is:

• 8 mg orally once daily
• May be taken with or without food

If treatment response and tolerance are favorable, physicians may consider dose adjustments.

⚠️ Avoid grapefruit juice and strong CYP3A4 inhibitors or inducers during treatment. Any dosage modification should be supervised by a healthcare professional.

📦 Medication Access Information

This platform supports patient access to internationally sourced Erdafitinib through regulated supply channels:

• Verified sourcing from original manufacturers or authorized pharmacies
• Electronic invoices and official shipment tracking available
• Multiple payment options supported, including credit card, Alipay, Apple Pay, and bank transfer
• Encrypted order handling and privacy protection throughout the process

Prescription review assistance and pharmacist consultation services are also available to help support safe medication use.

❓ Frequently Asked Questions (FAQ)

Q1: How can I know whether Erdafitinib is suitable for me?

A: FGFR2/3 mutation testing using tumor samples is required. Professional genetic testing coordination and medical evaluation may help determine eligibility.

Q2: How long does delivery usually take?

A: After order confirmation and payment completion, delivery generally takes approximately 5–10 business days depending on logistics and customs clearance.

Q3: Can Erdafitinib be combined with immunotherapy?

A: Some ongoing studies are evaluating combinations with immune checkpoint inhibitors, but widespread approval is still limited. Treatment decisions should follow physician guidance.

Q4: Can Erdafitinib be used long term?

A: Patients who continue to benefit and tolerate side effects may remain on treatment long term, with regular monitoring of liver function, kidney function, electrolytes, and ophthalmologic assessments.